Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05775718 · ClinicalTrials.gov registry record · Phase 2
Shingrix In Recipients of Allogeneic Transplants
A Phase 2 study of Stem Cell Transplant and Bone Marrow Transplant, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT05775718: Recruiting Phase 2 study of Stem Cell Transplant and Bone Marrow Transplant, sponsored by University of Colorado, Denver.
NCT05775718 is a Phase 2 study of Stem Cell Transplant and Bone Marrow Transplant that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 55 participants, below the 190-participant average among 9 other Stem Cell Transplant trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05775718, a Phase 2 study of Stem Cell Transplant and Bone Marrow Transplant, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is designed to determine if the adjuvanted recombinant glycoprotein E (gE) herpes zoster (HZ) vaccine (Shingrix) has acceptable immunogenicity and safety in people who have undergone allogeneic stem cell transplant (allo-SCT). Specifically, it will determine the effect of the interval after transplantation on the immune response and if an additional dose of vaccine is needed to improve the vaccine-induced responses.
Primary Outcome
To compare gE-specific CMI immune response of Cohort 1 in allo-SCT who received 2 doses of Shingrix ≥1 years post-transplantation and 18-30 months prior to enrollment across 3 groups defined by the time of vaccination after transplantation.
Conditions Studied
Interventions
- DRUG Zoster Vaccine Recombinant
Study Locations (1)
Colorado
- University of Colorado Hospital - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2023-10-24 |
| Est. Completion | 2030-12-01 |
| Phase | Phase 2 |
What NCT05775718 shows while recruiting
NCT05775718 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 190-participant average among 9 other Stem Cell Transplant trials with a reported enrollment target (71% lower).
The record links to 2 conditions, with Stem Cell Transplant appearing as the primary indexed condition, and to 1 intervention - of which Zoster Vaccine Recombinant is the first listed.
NCT05775718 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT05775718 about?
NCT05775718 is a clinical study titled "Shingrix In Recipients of Allogeneic Transplants". This research is designed to determine if the adjuvanted recombinant glycoprotein E (gE) herpes zoster (HZ) vaccine (Shingrix) has acceptable immunogenicity and safety in people who have undergone allogeneic stem cell transplant (allo-SCT). Specifically, it will determine the effect of the interval ...
What is the current status of trial NCT05775718?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2023-10-24. Estimated completion is 2030-12-01.
What conditions does trial NCT05775718 study?
This clinical trial studies the following conditions: Stem Cell Transplant, Bone Marrow Transplant.
What interventions are being tested in trial NCT05775718?
The interventions under investigation include: Zoster Vaccine Recombinant (DRUG).
Who is sponsoring clinical trial NCT05775718?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05775718 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stem Cell Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05775718's enrollment target sits among peer trials
55 7th of 9 higher than 3 of 9 other Stem Cell Transplant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stem Cell Transplant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Psychosocial and Behavioral Intervention for Stem Cell Transplant Patients and Their Family Caregivers
RECRUITING · NA
-
Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection
RECRUITING · NA
-
Behavioral Weight Loss Intervention Utilizing Mobile Health Technology in Hematopoietic Stem Cell Transplant Patients
RECRUITING · NA
-
BMT4me: Post-HSCT Medication Adherence mHealth App
RECRUITING · NA
-
Mosaic Trial for Stem Cell Transplant Recipients
RECRUITING · NA
-
Inpatient Palliative Care for Patients Undergoing Hematopoietic Stem Cell Transplantation
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI